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Summary
Mutations in the Plasmodium falciparum chloroquine (CQ) resistance transporter (PfCRT), are
major determinants of verapamil (VP)-reversible CQ resistance (CQR). In the presence of mutant
PfCRT, additional genes contribute to the wide range of CQ susceptibilities observed. It is not
known if these genes influence mechanisms of chemosensitization by CQR reversal agents. Using
quantitative trait locus (QTL) mapping of progeny clones from the HB3 × Dd2 cross, we show
that the P. falciparum multidrug resistance gene 1 (pfmdr1) interacts with the Southeast Asia-
derived mutant pfcrt haplotype to modulate CQR levels. A novel chromosome 7 locus is predicted
to contribute with the pfcrt and pfmdr1 loci to influence CQR levels. Chemoreversal via a wide
range of chemical structures operates through a direct pfcrt-based mechanism. Direct inhibition of
parasite growth by these reversal agents is influenced by pfcrt mutations and additional loci.
Direct labeling of purified recombinant PfMDR1 protein with a highly specific photoaffinity CQ
analogue, and lack of competition for photolabeling by VP, supports our QTL predictions. We
find no evidence that pfmdr1 copy number affects CQ response in the progeny, however,
inheritance patterns indicate that an allele-specific interaction between pfmdr1 and pfcrt is part of
the complex genetic background of CQR.
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Efforts against Plasmodium falciparum are hampered by the evolution and worldwide
spread of decreasing parasite susceptibility to an array of anti-malarial compounds,
including the near global failure of the former mainstay drug, chloroquine (CQ) (Ginsburg,
2005). Extensive field and laboratory research on CQ resistance (CQR) identified the crucial
role of a gene on chromosome (chr) 7, the P. falciparum CQR transporter (pfcrt), that
encodes a putative transporter with channel like properties, localized to the digestive vacuole
membrane in erythrocytic stage parasites (Cooper et al., 2002; Fidock et al., 2000; Martin et
al., 2009; Paguio et al., 2009; Sidhu et al., 2002; Su et al., 1997; Wellems et al., 1991;
Zhang et al., 2004). A K76T change is ubiquitous in CQ resistant populations worldwide
and is a reliable molecular marker of CQR (Best Plummer et al., 2004; Chen et al., 2003;
Djimde et al., 2001; Durrand et al., 2004; Plowe, 2003; Wootton et al., 2002).
Drug pressure in the laboratory to select mutant CQ resistant parasite lines has been
successful in only one CQ sensitive (CQS) parasite line, 106/1 (Cooper et al., 2002), which
is unique in harboring six of the seven PfCRT mutations characteristic of Southeast Asian
CQ resistant parasites, lacking only the critical K76T (Su et al., 1997). Attempts to select for
CQR using other CQS parasite lines have failed (Lim and Cowman, 1996). In other
experiments, the wild-type PfCRT allele of GC03, a CQS progeny clone of the HB3 × Dd2
genetic cross with a haplotype of CMNKAQNIR at amino acid positions 72, 74, 75, 76, 220,
271, 326, 356, and 371, was replaced with three unique CQ resistant haplotypes:
CIETSESTI (Dd2), CIEISESII (106/176I), and SMNTSQDLR (7G8) by homologous
recombination (Sidhu et al., 2002). Each of these replacements conferred a distinct CQR
phenotype in GC03 (Lakshmanan et al., 2005; Sidhu et al., 2002). Collectively, these studies
underscore the major role of amino acid 76 in CQR, but also indicate an important role for
additional factors in the genetic background of the key PfCRT mutation.
The suggestion that multiple genetic factors underpin CQR was raised more than 20 years
ago, well before the identification of pfcrt (Foote et al., 1990). A strong but incomplete
association of mutations in pfmdr1, a gene encoding a P-glycoprotein homologue (Pgp) of
the human multidrug resistant (MDR) efflux pump (McGrath et al., 1989; Shen et al., 1986),
with CQR in field isolates (Foote et al., 1990), combined with the observation that pfmdr1
mutations were not linked with CQS or CQ resistant progeny of the HB3 × Dd2 cross
(Wellems et al., 1990), spurred a lasting debate about this gene’s role in the mechanism and
evolution of CQR (Bray et al., 1998; Krogstad et al., 1987; Orjih et al., 1994; Sanchez et al.,
2003; Sanchez et al., 2005; Yayon et al., 1984). This incongruity led to the suggestion that
some CQS parasites may be competent to become CQ resistant with the acquisition of
additional mutation(s) (Foote et al., 1990). Pfmdr1 point mutations have been associated
with CQR (Foote et al., 1989; Foote et al., 1990; Mu et al., 2003; Wilson et al., 1989),
however these associations vary geographically, leaving the role of pfmdr1 in CQR
modulation and reversibility unresolved (Adagu and Warhurst, 2001; Chen et al., 2002;
Duraisingh and Cowman, 2005; Hayton and Su, 2004; Rason et al., 2007; Sidhu et al.,
2006). PfMDR1 overexpressed in Xenopus laevis oocytes transports quinine (QN),
halofantrine and CQ in a mutation specific manner, but only wild type PfMDR1 transported
CQ in this model (Sanchez et al., 2008). In Pichia pastoris, heterologous PfMDR1
expression catalyzes drug-stimulated ATPase activity (Amoah et al., 2007; Lekostaj et al.,
2008a).
Pfcrt and pfmdr1, among other loci, interact to affect QN dose responses, leading us to
propose that local drug selection in different geographic regions can differentially shape the
gene interactions and their impact on a range of drug resistance phenotypes (Ferdig et al.,
2004; Sen and Ferdig, 2004). Two recent studies, one using classical genetics (Sa et al.,
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2009) and the other reverse genetics (Valderramos et al., 2010), demonstrated the pivotal
influence of the parasites’ genetic backgrounds (i.e. distinct drug selection histories) into
which the key CQR-conferring pfcrt mutations are successfully inherited or experimentally
introduced.
A hallmark of CQ resistant parasites is that particular compounds can re-sensitize them to
CQ, a phenomenon termed “reversibility” (Martin et al., 1987). A similar reversal effect was
first observed in MDR mammalian tumor cells (Rogan et al., 1984; Tsuruo et al., 1982), and
many classes of compounds have now been identified that can reverse CQR (Kyle et al.,
1990; Pradines et al., 2005). One of the earliest identified reversal agents was verapamil
(VP), a Ca2+ channel blocker indicated for the treatment of angina pectoris, cardiac
arrhythmias, and hypertension. In human tumor cells, VP-dependent chemosensitization is
believed to be mediated by Pgp (McGrath et al., 1989; Shen et al., 1986). Because VP was
found to re-sensitize CQ resistant P. falciparum to near CQS levels, a Pgp efflux mechanism
was considered the likely basis of CQR. Three-dimensional quantitative structure activity
relationship studies generated a pharmacophore model for a group of tri-cyclic
antidepressants that reverse CQR (Bhattacharjee et al., 2002). Two hydrophobic, aromatic
regions with a nitrogen atom acting as a hydrogen-bond acceptor are apparently required for
CQR reversal activity (Bhattacharjee et al., 2001). This model accommodates a variety of
CQR reversal agents that span distinct chemical classes, including VP, cyproheptadine,
ketotifen, chlorpheniramine (CLM), and citalopram (CT). Two theories have been proposed
for VP reversal of CQR: 1) the ‘drug transporter’ hypothesis argues that VP competes with
CQ for target binding and perhaps drug transport in resistant parasites (Bray and Ward,
1998; Martiney et al., 1995; Sanchez et al., 2004), and; 2) VP may act on ion transport to
alter the compartmental pH and/or membrane potentials to levels found in CQS parasites
(Bennett et al., 2004; Martiney et al., 1995; Roepe and Martiney, 1999; Ursos et al., 2000).
Both hypotheses are possibly relevant, as drug transport by drug resistance proteins could be
due to direct or indirect ion mediated co-transport (Zhang et al., 2004). CQR reversibility by
VP and the 8-aminoquinoline, primaquine (Bray et al., 2005), like CQR itself, has been
attributed to PfCRT, yet the possibility of non-target based mechanisms suggests the
interaction of multiple transporters. Reversal agents themselves are toxic to the parasites
(Adovelande et al., 1998; Menezes et al., 2002, 2003), but it is not known if these
structurally diverse reversal agents exert their toxic effect solely by PfCRT or involve
additional genes, nor if their inherent anti-plasmodial effects predict the degree of
reversibility of CQR. For example, some CQ resistant parasites such as the South American
7G8 strain, are less responsive to the VP reversal effect (Mehlotra et al., 2001; Sa et al.,
2009). It is not known if factors that contribute to the wide range in CQ IC50 values among
CQ resistant field isolates, even in the presence of identical PfCRT alleles (Mu et al., 2003),
can also influence reversibility.
PfCRT has been the overriding focus of recent studies of CQR and its coupled reversibility
by VP. To search for additional contributing genes we measured quantitative CQ
susceptibility and its reversibility by various pharmacological classes of compounds,
including VP, CLM, CT, probenecid (PB) and amitriptyline (AM) in progeny of the HB3 ×
Dd2 genetic cross. Using 33 independent progeny, we use quantitative trait locus (QTL)
profiles to probe the complex genetic background of the Southeast Asia-derived CQR and its
functional relationship to reversal. This approach revealed a dynamic interplay of major and
minor shared loci highlighting gene adaptations influencing CQR, reversibility, and fitness.
The contribution of pfmdr1 and a putative secondary locus on chr 7 locus to CQR is
reported. Pfcrt controls the vast majority of reversal by a range of compounds. We find no
evidence that pfmdr1 copy number (CN) affects CQ IC50 values, however, co-inheritance of
specific pfmdr and pfcrt allele combinations in individual progeny underscores a complex
genetic background of CQR.
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Quantitative effects of reversal agents, independently and in combinations, in the parental
lines
Six reversal agents – VP, CT, AM, CLM, PB, and desipramine (DES) – spanning various
pharmacologically active drug classes were tested in combination with CQ. Fractional
inhibitory concentrations (FIC) (Elion et al., 1954) at each of the fixed molar ratios for all
drug combinations were determined for both HB3 and Dd2 to quantify the type and degree
of interactions between the reversal agent and CQ. When plotted as isobolograms,
synergistic effects were observed for Dd2 in combinations of CQ+VP (Fig. 1A), CQ+CT
(Fig. 1B), CQ+AM (Fig. 1D), CQ+DES (Fig. 1E), and CQ+CLM (Fig. 1F), whereas all
combinations were additive in HB3. PB was not synergistic in Dd2 (Fig. 1C), contrary to a
previous observation in the CQ resistant strain, V1/S (Nzila et al., 2003); however, a recent
report from this same group (Masseno et al., 2009) revised their assessment of PB reversal
of V1/S CQR to be 5-fold less synergistic. We confirmed a linear or slightly additive
relationship between PB and CQ for both HB3 and Dd2.
Based on the comprehensive analysis of the parent clones, a single fixed dose combination
was used to construct a measure of reversibility for replicate testing of 33 progeny clones.
The fixed dose volumetric ratio of 9:1, representing the lowest concentration of reversal
agent that showed synergism (Fig. 1) was used for all drug combinations examined in the
progeny (CQ+VP, CQ+CLM, CQ+CT, and CQ+AM). The starting concentration for the 2-
fold serial dilutions (see methods) were CQ:VP – 2.25 μM : 24.03 μM, CQ:CLM – 2.25
μM : 71.01 μM, CQ:CT – 2.25 μM : 6.85 μM, and CQ:AM – 2.25 μM : 22.30 μM. CQ IC50
values in HB3 and Dd2, with and without reversal agent, demonstrated that reversal agents
did not significantly alter the CQ response in HB3 (p > 0.05, n = 5), whereas highly
reproducible reversibility (n = 18-22) was achieved with each of the four combinations in
Dd2 (Fig. S1). The combination of CQ+AM was the most potent, lowering the IC50 of CQ
to 59.2 ± 3.12 nM, whereas CQ+CT was the least potent, lowering the IC50 to an
intermediate level of 117.3 ± 6.84 nM in Dd2. Table 1 summarizes the inherent IC50 values
for VP, CLM, and CT when tested independently. Dd2 was more sensitive to VP, CLM, and
CT than HB3, with more than 6-, 45-, 20-fold differences, respectively. Dd2 was only
slightly more sensitive to DES (1.4-fold) than HB3, and no difference was observed between
the parent lines for PB IC50 values (data not shown).
Reversibility in the progeny of the genetic cross
Only the reversal agent-CQ combinations that showed strong synergy in Dd2 were carried
over into a full analysis of the progeny. Mean IC50 values from VP, CLM and CT, alone and
in combination with CQ, were obtained from five independent replicates for each of the
progeny of the genetic cross (Table S1). Values were continuously distributed for each
compound, with no clear IC50 gap dividing the progeny into two classes that would be
expected if a single gene determined the phenotype. CQS progeny were less sensitive to VP
alone than CQ resistant progeny (Fig. 2A, p < 0.01), and this dichotomy was consistent for
all the reversal agents.
Among the progeny, IC50 values ranged from 18.3-771.0 nM for CQ and 17.8-105.1 nM for
CQ+VP. A relative measure, computed as fold change, was used to assess the degree of
reversibility. For each drug combination, the fold change distribution divided the progeny
into two groups that coincided with the inherited pfcrt allele and therefore CQ resistant or
CQS status (Fig. 2B). CQ susceptibility in the presence of VP for both CQS (Fig. 3A) and
CQ resistant (Fig. 3B) progeny was strongly correlated with CQ response in the absence of
VP; however, no significant changes were observed in CQ susceptibilities of CQS progeny
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in the presence of VP (fold change 1.1 ± 0.1, p > 0.05), whereas significantly lower IC50
values were detected in CQ resistant parasites (6.6 ± 1.1 fold change, p < 0.0001) in the
presence of VP. The degree of reversibility (fold change ranging from 4.7-8.1) was
independent of the inherent CQ IC50 values in CQ resistant progeny (Fig. 3C) (r = 0.2, p >
0.05), and the primary reversal mechanism for all three compounds depended on pfcrt
mutations. Highly significant correlations were observed among fold-changes induced by
the 4 compounds in CQ resistant progeny (Table S1) (r values ranging from 0.89 to 0.95),
indicating that a common additional gene(s) controls the degree of reversibility. Regression
analyses of the relationships between CQ IC50 and the potencies of the reversal agents and
fold change are provided in Table 2. Negative correlations were detected between CQ IC50
values and VP, CLM, and CT IC50 values, whereas fold change resulting from CQ+reversal
agent was strongly positively correlated with the CQ IC50. When these analyses were
performed individually on the CQS and CQ resistant subgroups, the relationship between
fold change and CQ IC50 was lost in both sub-groups, indicating that secondary influences
on CQ IC50 values do not affect fold change. However, positive relationships were
identified for CLM and CT potencies with CQ IC50 in both CQS and CQ resistant progeny,
suggesting that secondary genetic determinants of quantitative CQ susceptibility in these
sub-groups may influence CLM and CT response.
QTL analysis of drug responses
Genome-wide QTL scans for VP, CLM, CT, CQ, and CQ+VP responses are presented in
Fig. 4. VP, tested independently (Fig. 4A), revealed a significant chr 7 QTL at 20.2 cM (log
of odds [LOD] = 6.9) in the region of pfcrt. In addition, a suggestive QTL was identified on
chr 5 (LOD = 2.3) that mapped to the marker at position 68.8 cM in the region of pfmdr1.
CLM (Fig. 4B) and CT (Fig. 4C), tested independently, each revealed two QTL: a
significant QTL on chr 7 (20.2 cM, LOD = 47 and 28, respectively) and a suggestive QTL
on chr 5 (68.8 cM, LOD = 2.7 and 2.9, respectively). The substantial coincidence of the chr
5 (pfmdr1) and chr 7 (pfcrt) QTL for VP, CLM, and CT was consistent with a relationship
between these two loci in controlling sensitivities to VP, CLM, and CT. The genome-wide
scan for CQ sensitivity detected a single highly significant QTL with a LOD = 39 (Fig. 4D).
Fold change resulting from combining each reversal agent with CQ revealed a single shared
QTL on chr 7 (20.2 cM) with even higher LODs than were observed for CQ response (e.g.
Fig. 4E).
Allelic effects for the chr 5 (68.8 cM) and chr 7 (20.2 cM) loci (Fig. 5A and B, respectively)
indicated that higher IC50 values for VP, CLM, and CT drug responses were associated with
the HB3 allele at both loci. For CQ response, the Dd2 allele on chr 7 (20.2 cM) was
associated with a higher IC50 and a greater fold change in the presence of a reversal agent.
Figure 5C and D show an overlay of QTL highlighting the shared QTL on chrs 5 and 7,
respectively. This shows that at least two, and probably more loci influence the response to
reversal agents by themselves, commensurate with the continuous distribution of those traits.
However, CQ response reversibility is solely dependent on the chr 7 genetic effect that
generates a two-class phenotype as a result of mutations in pfcrt (Cooper et al., 2002; Fidock
et al., 2000; Sidhu et al., 2002). To investigate the genetic basis of the highly correlated
degree of reversibility induced by VP, CT, AM and CLM in CQ resistant progeny, measured
as fold change, we conducted QTL scans directly on this sub-class of progeny. A QTL peak
on chr 11 (48.8 cM) in the region of marker C12M42 at 701,403 bp, passed the suggestive
LOD threshold for fold-change with all 4 compounds (data not shown).
Identification of genetic loci affecting the range of susceptibilities in CQ resistant progeny
The rank order distribution of CQ response in the progeny is bimodal, as originally
demonstrated by Wellems et al. (1990), and as is expected for a single major gene. In that
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early work, microscopy-based evaluation of parasitemias showed identical IC50 values for 8
CQS and 8 CQ resistant progeny, and these two discrete classes did not segregate with the
pfmdr1 marker allele, proving that in the HB3 × Dd2 progeny pfmdr1 was not the
determinant of CQR. Here we used 33 progeny and multiple independent replications of
radiolabeled-hypoxanthine incorporation to observe continuous distributions of quantitative
CQ susceptibility within both the CQS (18-38 nM) and CQ resistant (266-771 nM) sub-
groups (Fig. 6A). We examined only the CQ resistant progeny for further analyses to
specifically map QTL contributing to the wide range of CQ IC50 values in the resistant class
inheriting mutant pfcrt. This approach eliminates the contribution by pfcrt effect because
each of the CQR progeny carried the identical Dd2 pfcrt allele. We identified two secondary
loci, on chrs 5 and 7. The chr 5 QTL again mapped to 68.8 cM in the region of pfmdr1, with
a LOD = 2.5, and the novel chr 7 QTL mapped to 5.8 cM with a LOD = 2.0 (Fig. 6B and
Table S2). The allelic effect plots indicate that the chr 5 (68.8 cM) HB3 allele and the chr 7
(5.8 cM) Dd2 allele contributed to the highest CQR IC50 values (Fig. 6C). Because we
observed a suggestive chr 5 QTL peak in this subset of progeny, we further examined the
relationship between pfmdr1 and the Dd2 type pfcrt allele by employing the statistical
method described by Sa et al. (2009) to directly test the influence of different pfmdr1 alleles
on CQ IC50 values. Four different allele pair combinations were possible for pfmdr1 and
pfcrt: D5D7, H5D7, D5H7, and H5H7 (D represents an allele inherited from Dd2, and H
represents an allele inherited from HB3). The pfmdr1 locus significantly influenced the CQ
IC50 only in CQ resistant progeny; we detected a 1.57-fold shift in CQ susceptibility (p <
0.01) depending on the source of the pfmdr1 allele in combination with mutant pfcrt. CQR
progeny with the H5D7 combination have significantly higher IC50 values than D5D7 (Fig.
6C). Because this difference was not detected in a recent study (Sa et al., 2009), we
validated our findings. The rank order of CQ IC50 values, 1BB5 > QC03 > 3BD5 in our
study, contributed most to the differing results between the two studies. Because we use CQ
as a control drug in our ongoing drug assays, 4 independent replicated analyses of the
complete progeny set were available in our database and each demonstrated the same
statistically significant rank order (1BB5 > QC03 > 3BD5) (data not shown). We also
reanalyzed CQ IC90 values from the HB3 × Dd2 cross (Ferdig et al., 2004) using the same
alternative statistical model outlined here and found a 1.4-fold CQ IC90 difference (p < 0.01)
between D5D7 and H5D7 progeny, with the latter combination most resistant.
PfMDR1 CN and observed allele combinations in the progeny clones
Pfmdr1 CN was determined for all progeny (Table S3). The Dd2 parent has 3 copies while
HB3 has a single copy. We observe 9 progeny with 2 copies and 3 additional progeny with
the Dd2 pfmdr1 allele and CN = 1. Non-parental CN were reported previously for partial
sets of HB3 × Dd2 progeny (Rohrbach et al., 2006; Wellems et al., 1990) and increased CN
shows increased expression levels of PfMDR1 (Rohrbach et al., 2006; Wilson et al., 1989).
Here we confirm and extend the findings of the inherited variation in CN, noting that the
HB3 pfmdr1 allele is always present as a single copy, while the Dd2 allele varies from 1-4
copies across the progeny set. We have confirmed the in vitro stability of CN by culturing
10 progeny clones for 30-45 replication cycles and observing no change in CN (data not
shown).
It is difficult to determine the direct impact of pfmdr1 CN on CQ IC50 values because the
allele effects cannot be precisely separated from the CN effects in progeny carrying 1 vs. 2
copies. However, a direct comparison of IC50 values of CQ resistant parasites with 2 vs. 3 or
more copies, all of which contain Dd2 pfcrt and pfmdr1 alleles, reveals no correlation (r =
-0.02) and no difference in the mean IC50 values (p = 0.59). Furthermore, we statistically
removed the contribution of pfcrt and compared the residuals of mean CQ IC50 values in the
complete progeny set and found that CN (1 vs. >1, p = 0.044) accounted for somewhat less
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of the residual variation than point mutations alone (HB3 vs. Dd2, p = 0.02). Consequently,
our data do not support a role for CN in influencing CQ susceptibility. However, several
observations support co-adaptation between pfmdr1 CN and pfcrt. Inherited combinations of
these loci in the progeny clones suggest an influence on fitness as surmised from the
combinations that exist among the progeny: i. of 33 progeny analyzed, 15 inherited the Dd2
pfmdr1 allele, but only 3 retained the full complement of 3 copies; each of these 3 carries the
mutant pfcrt. Twelve of 15 progeny with the Dd2 pfmdr1 allele lost at least one pfmdr1 copy
in the establishment of the stable progeny clonal lines ; ii. all progeny carrying the single
copy Dd2 pfmdr1 allele are CQS, carrying the wild type pfcrt; iii. all 5 of the progeny with
the D5H7 allele combination carry fewer than 3 copy. High CN is maintained only in the
context of its co-selected mutant pfcrt partner, and CQS pfcrt is never paired with 3 copies
of pfmdr1 (Table S3).
Binding of a high affinity CQ analogue to PfMDR1
Recently, the CQ binding site for wild-type PfCRT was defined using a novel photoaffinity
chloroquine analogue, azido-biotinylated chloroquine (AzBCQ) (Lekostaj et al., 2008b).
Using this same method and overexpression of recombinant PfMDR1 (Amoah et al., 2007;
Lekostaj et al., 2008a), we tested whether the high affinity AzBCQ probe would bind to 3D7
(wild type), Dd2, and 7G8 isoforms of purified recombinant PfMDR1 protein reconstituted
into proteoliposomes (PLs) as recently described elsewhere (Pleeter et al., 2010). Figure 7
demonstrates that binding of AzBCQ to PfMDR1 reveals CQ affinity for PfMDR1. A 40-50
fold molar excess of CQ reduces efficiency of AzBCQ photolabeling to < 30% of control for
3D7 and Dd2 isoforms of PfMDR1 (Fig. 7A; lanes 2 vs. 1 and 5 vs. 4, respectively).
Apparent CQ affinity for the 7G8 isoform is slightly reduced (competition to < 40% of
control, Fig. 7A; lane 8 vs. 7) relative to the other isoforms. Averaged over 3 experiments
and 2 independent PL preparations for each isoform of PfMDR1, we did not identify
pronounced VP competition for AzBCQ photolabeling to any isoform of PfMDR1 (Fig. 7C),
in contrast to our earlier demonstration of VP competition for AzBCQ photolabeling of the
3D7 and Dd2 isoforms PfCRT (Lekostaj et al., 2008b).
Discussion
After decades of remarkable success, CQ is no longer used against P. falciparum in most
regions of the world due to the evolution of resistance (Wellems and Plowe, 2001).
Selection by CQ was the first step towards the evolution of modern-day MDR parasites, yet
questions remain about how CQR evolved and why CQR parasites persist long after CQ
disuse. Answers to these questions will inform a more strategic development and
deployment of drugs against MDR parasites.
The classical genetics approach relies on Mendelian recombination and segregation to
shuffle the naturally evolved allele combinations that have been fine-tuned by selection
pressures on the parental genomes. By crossing two parents with distinct evolutionary
histories, e.g. drug selection pressures applied in different geographic regions, the divergent
signatures of selection in these genomes can be identified by QTL mapping. The strength of
this approach was illustrated in a recent study comparing the genetic control of CQ and
amodiaquine susceptibilities in progeny from two crosses between parents carrying a range
of drug selection histories (Sa et al., 2009).
Here, we rely on the P. falciparum HB3 × Dd2 genetic cross (Wellems et al., 1990) to
dissect the quantitative response to CQ, and to identify genetic loci that influence the
reversibility of CQR. HB3 is a CQS parasite derived from Honduras. The progenitor of Dd2
was derived from a Laotian patient who failed CQ therapy (Campbell et al., 1982), and this
line also has high-level resistance to pyrimethamine. Dd2 was cloned from W2-mef which
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was selected in the laboratory by mefloquine (MQ). Consequently, the MDR Dd2 genome
has been shaped by sequential drug selections and carries the Southeast Asia-derived CQ
resistant PfCRT haplotype, referred to here as CVIET (amino acid positions 72-76).
A wide range of compounds can reverse CQR. By adapting the QTL methodology to
compare a range of CQ chemosensitizers, we explored the genetic components of
reversibility, represented by fold-change of CQ IC50 induced by several reversal agents.
Furthermore, we examined the potencies of the individual reversal compounds. Continuous
distributions were observed for the inherent potencies of VP (Fig. 2A), CLM, and CT and
susceptibility to these compounds was inversely correlated with CQ response. Previously
VP was shown to have greater potency against CQ resistant parasites (Gerena et al., 1992),
as have various antihistaminics (Peters et al., 1989, 1990) and amantadine (Johnson et al.,
2004). Models predict binding of amantadine, a proton channel blocker, to the putative
PfCRT pore of CQ resistant parasites that could interfere with the transport of a critical
substrate, resulting in parasite death (Johnson et al., 2004; Wellems, 2004). This and other
observations suggest that specific PfCRT binding by reversal agents underscores the
potential of this transporter as a drug target. The continuous phenotype distributions indicate
that multiple genes contribute to these traits. QTL analyses of the direct responses to VP,
CLM, and CT (Fig. 4 A-C) identified two loci shared by all three reversal agents. The QTL
on chr 5 maps to a marker at 68.8 cM in the region of pfmdr1 (Fig. 5C) and the QTL on chr
7 maps to the marker at 20.2 cM in the region of pfcrt (Fig. 5D). These shared QTL indicate
that parasite susceptibility to these structurally and pharmacologically distinct compounds is
controlled by similar mechanisms that depend on both pfcrt and pfmdr1. The HB3 allele at
both loci is associated with higher drug IC50 values in the progeny (Fig. 5A and B). No
other statistically significant loci were detected for these compounds, leaving unclear where
additional factors controlling these complex traits reside.
In contrast to the individual effects by these compounds, genome-wide scans for
reversibility maps to a single locus on chr 7 (20.2 cM) in the region of pfcrt. All
combinations [CQ+VP (Fig. 4E), CQ+CLM, CQ+CT, and CQ+AM] had exceptionally high
LOD scores, indicating that reversibility of CQR is predominantly determined by pfcrt for
all drug combinations. This observation is consistent with the recent observations that VP
inhibits CQ transport (Martin et al., 2009; Paguio et al., 2009) and competes for labeling of
recombinant purified PfCRT by a photoaffinity CQ analog (Lekostaj et al., 2008b).
Correspondingly, that we observed no effect by pfmdr1 on reversibility agrees with the lack
of significant disruption by VP of PfMDR1-AzBCQ binding (Fig. 7). Our observation of a
direct determination of reversibility by pfcrt mutations concurs with the recent evidence that
CQ reversal agents are substrates for PfCRT and possibly inhibit CQ transport by a
competitive mechanism (Lehane and Kirk, 2010). Our findings are restricted to the CVIET
pfcrt allele carried by the Dd2 parent; other reports indicate that VP has less potency as a
CQR reverser in the context of the SVMNT allele (Mehlotra et al., 2001; Sa et al., 2009),
perhaps because VP is not a substrate for this form of pfcrt (Lehane and Kirk, 2010). We
also identified a candidate locus on chr 11 controlling the 4- to 8-fold increase in CQ
susceptibility induced by all 4 reversal agents. Although this is a modifying locus in HB3 ×
Dd2 progeny, it could point to a gene or pathway that plays a prominent role in the more
subtle form of reversal observed in 7G8 that is not strongly linked to PfCRT mutations.
The HB3 × Dd2 P. falciparum genetic cross (Wellems et al., 1990) was generated to
localize the determinant of CQR. For those studies, CQ susceptibility was treated as a
bimodal trait such that each progeny was assigned to a subclass – CQS or CQ resistant. This
approach is effective for mapping a major genetic determinant and led to the identification
of the chr 7 locus (Wellems et al., 1991), followed by positional cloning of pfcrt and
eventual identification of the critical K76T mutation (Fidock et al., 2000; Su et al., 1997).
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QTL analyses relies on precise measurement of continuous phenotypes and can reveal both
major and minor gene contributions and define the interactions among the identified loci
(Ferdig et al., 2004). QTL analyses of CQ resistant progeny removes the dominant pfcrt
effect and points to two suggestive QTL [on chr 5 (68.8 cM) and on chr 7 (5.8 cM)] that
account for ~70% of the phenotypic variance inherited in CQ resistant individuals (Fig. 6B).
We found that the pfmdr1 locus significantly influenced CQ IC50 values in CQ resistant
progeny, producing a 1.57-fold shift in CQ susceptibility. The effect of pfmdr1 in generating
distinct levels of CQR in the HB3 × Dd2 cross is weaker than the nearly 2-fold shift induced
in the progeny from the 7G8 × GB4 cross that carries the7G8 pfcrt allele from South
America (SVMNT) (Sa et al., 2009).
The insight of Sa et al. that different drug use in different geographic regions will result in
differentially tuned allele combinations may also be relevant here. Specifically, these
authors propose that pfmdr1 mediates a more stable, persistent form of CQR in South
America and that this advantaged pfmdr1 × pfcrt allelic combination may be induced in
Africa by increased use of amodiaquine. The observation that low level QN resistance in the
HB3 × Dd2 cross exhibited a positive correlation with CQ IC90 values in CQ resistant
parasites led to the suggestion that secondary loci selected by QN pressure, including
pfmdr1, could incrementally influence CQ and other drug susceptibilities through a complex
adaptive role among various polymorphisms (Ferdig et al., 2004). That is, amplification of
and site-specific changes in pfmdr1 associated with QN susceptibility (Cowman et al., 1994;
Reed et al., 2000), could, in turn, have influenced the stability of CQR in Southeast Asia and
Africa through co-adapted allele combinations.
We observed that CQ resistant progeny that inherited an HB3 allele at pfmdr1 produced the
highest CQ IC50 values (Fig. 6C). This observation concurs with the observation that 7G8 ×
GB4 progeny that inherited the GB4 (CVIET) PfCRT allele show a smaller shift in CQR
levels (1.4 fold) induced by the co-inherited pfmdr1 allele (Sa et al., 2009). In both crosses,
it is the mismatched pfmdr1 allele – the allele not originating from the CQ resistant parent
with the CVIET haplotype – that is associated with the highest levels of CQR among the
respective progeny. Importantly, this is in contrast to the situation for the 7G8 form of pfcrt
(SVMNT) that produces its highest levels of CQR when matched with its co-evolved 7G8
pfmdr1 partner. Notably, the levels of resistance produced by SVMNT are considerably
lower than those produced by CVIET PfCRT, which originated in Southeast Asia and later
spread to Africa (Wootton et al., 2002). The unmatched allele combination, GB4 pfmdr1 –
7G8 pfcrt exhibited a strikingly low level of CQR, with nearly 2.5-fold lower IC50 values
than the average CVIET progeny, perhaps near the limit of surviving therapeutic CQ doses.
Considered in total, these observations imply that pfmdr1 and pfcrt are co-evolved in the
respective CQ resistant parent genomes to optimize cell function and compensation rather
than to maximize CQR levels.
Analogous to the persistence of SVMNT CQR pfcrt allelles in South America (Contreras et
al., 2002; Vieira et al., 2004), CQ resistant parasites continue to predominate in Thailand
more than 25 years after cessation of CQ therapy (Brockman et al., 2000; Mu et al., 2005;
Price et al., 2004), even while carrying the CVIET form of pfcrt that has been suggested to
be less fit in some genetic contexts. For example, CQ sensitivity has reemerged in Malawi,
where CQR was once widespread but CQ is no longer used (Kublin et al., 2003; Laufer et
al., 2010; Mita et al., 2003), and in Hainan, China, where over a 10 year period CQR
prevalence decreased from 98% to 61% (Liu et al., 1999). In these cases, CQ sensitivity
returned steadily by re-integration of the complete CQS genomes, not by point mutant
reversions that would be predicted for a single gene resistance with strong fitness costs.
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Hastings et al. recognized that introduction of pfcrt mutations alone was sufficient to induce
CQR only in certain genetic backgrounds (Hastings et al., 2002; Sidhu et al., 2002), noting
that the definitive experiment would require the introduction of these mutations into a series
of different genetic backgrounds. Valderramos et al. recently demonstrated the critical role
of genetic background on the ability of the 7G8 pfcrt allele to confer CQR (Valderramos et
al., 2010); they induced phenotypes in a variety of CQS backgrounds that ranged from high-
level CQR (GC03, a progeny of the HB3 × Dd2 cross) to no change in IC50 but an increased
rate of recrudescence (D10, Papua New Guinea). Parasite lines with identical pfmdr1 alleles
transfected with the same pfcrt allele showed distinct CQ resistant phenotypes, underscoring
the role of genes other than pfmdr1 and pfcrt. Moreover, the Dd2 pfcrt allele could not be
used to successfully transform three different CQS background:, 3D7, D10 and HB3. Only
GC03, carrying half of its genome from Dd2, has been successfully transfected with the Dd2
pfcrt, giving rise to high-level CQR. Because HB3 and GC03 carry identical single copy
pfmdr1 alleles, we can again infer that an additional gene(s), co-selected in the Dd2 parent,
must contribute to the competency of a CQS parasite to support the large effect CQR
mutations. Notably, the mutational steps that gave rise to the few independently evolved
CQR origins remain unknown. One possible candidate is an epistatic partner of pfcrt
residing in the chr 6 locus was shown previously to regulate low level QN resistance and
associate with slow in vitro expansion rates of progeny inheriting the HB3-type chr 6 and
Dd2-type pfcrt loci (Ferdig et al., 2004).
Dd2 and HB3 differ both in point mutations and CN for pfmdr1: Dd2 (86Y, 184Y, and
1042N) maintains three copies of pfmdr1, while HB3 (86N, 184F, and 1042D) maintains a
single copy. In an effort to evaluate the relative contribution of point mutations and CN on
CQ susceptibility, we determined CN for the complete progeny set. Previous studies
demonstrated that increased copies of pfmdr1 coincided with an increase in PfMDR1 protein
levels (Rohrbach et al., 2006). Allelic exchange studies to understand the role of amino acid
changes in PfMDR1 have been limited to the carboxyl region that includes 1042N;
replacement of the pfmdr1 3’ polymorphisms in CQ resistant progeny 3BA6 with the Dd2-
allele (D1042N) did not significantly alter CQ response (Sidhu et al., 2005) but did not rule
out that either the 5’ region (86Y, 184Y) and/or pfmdr1 CN influence CQR levels. The
placement of D10 pfmdr1 3’ polymorphisms in the 7G8 background led to a 2-fold decrease
in CQ response (Reed et al., 2000). When pressured with CQ, parasites with multiple
pfmdr1 copies lose extra copies of the gene (Barnes et al., 1992; Peel et al., 1994), with no
other mutation in pfmdr1 or pfcrt, suggesting that excessive copies may have a fitness cost.
We found no difference in CQR levels attributable to CN. Moreover, most progeny with the
Dd2 pfmdr1 allele do not carry the parental complement of 3 copies. CN change is
commonly reported in response to in vitro drug pressure (Barnes et al., 1992; Chavchich et
al., 2010; Wilson et al., 1989), and a reduction in CN has been observed after removal of
artelinic acid pressure (Chen et al., 2010); the rate of CN loss and the final stable numbers of
copies is a characteristic of individual parasite lines. We have observed that CN is stable in
long-term culture in these progeny, suggesting that the relationship of allele combinations at
pfmdr1 and pfcrt is fine-tuned. High CN thrives only in the context of its co-evolved
genome that includes Dd2 type pfcrt, whereas CQS pfcrt prefers a single copy of pfmdr1
(Table S3).
Pfmdr1 knockdown by gene disruption for FCB (86Y, 184Y, and 1042N) showed no
significant changes in CQ susceptibility (Sidhu et al., 2006). Association studies in natural
CQ resistant populations have identified a significant role for pfmdr1 86Y and pfcrt 76T in
CQR (Babiker et al., 2001; Mittra et al., 2006), but the presence and strength of these
associations varies geographically. The frequencies of both these alleles are on the rise in
regions of India under intense CQ selection (Mittra et al., 2006). However, in Thailand,
where CQ is no longer used and MQ pressure led to increased pfmdr1 CN, CQ resistant
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parasites uniformly carry pfmdr1 86N (Price et al., 2004). An apparent conflict exists
between 86Y and increased CN such that CN increases often associated with selection by
MQ, artemisinin, and lumefantrine, coincides with the loss of 86Y (Uhlemann et al., 2007).
It is unusual to find the 86Y mutation with increased CN, but it has been reported in natural
isolates collected prior to emergence of MQ resistance (Looareesuwan et al., 1992; Sidhu et
al., 2007; Uhlemann et al., 2005). Both point mutations in pfmdr1 and increased CN have
been widely associated with fitness costs during asexual, erythrocytic growth in the absence
of drug pressure in field isolates (Osman et al., 2007), allelic replacements (Hayward et al.,
2005), and drug selected mutants (Preechapornkul et al., 2009).
It may be that the coincidence of 86Y and increased copy number is a transitional state that
has been captured in the Dd2 line by in vitro MQ selection on W2. In the HB3 × Dd2
progeny, the combination of PfMDR1 86Y and PfCRT 76T confers only low-level CQR and
the progeny that inherited 86N combined with a single copy of pfmdr1 have the highest
CQR levels. This is consistent with the co-adapted combination of Dd2 alleles at these two
loci reflecting a tradeoff between the level of CQR and fitness.
Classical genetics and QTL mapping can compliment gene manipulations using trasfection
methods to explore the basic biology of CQR. Pfcrt mutations are well known to be at the
center of CQR and its reversibility however accumulating evidence points to an important
role for additional factors that influence these traits as well as parasite fitness. We show that
many structurally distinct reversal agents restore CQ susceptibility through a PfCRT
mechanism. Furthermore, although pfcrt is the determinant of large phenotypic differences
between CQ resistant and CQS parasites, secondary loci can be identified for CQ
susceptibility and reversibility. These loci can point to genes that may interact with the
endogenous function of pfcrt or may cause effects through indirect physiological
mechanisms. Understanding these interacting/alternative pathways and their co-selection by
drug may illuminate the evolutionary path to CQR and, more importantly, refine strategist to
limit new resistances.
Experimental procedures
Parasites, genotypes, and culturing
The HB3 (Honduras) and Dd2 (Indochina) clonal parental isolates and 35 clonal progeny
lines are from the same cross previously used to construct the P. falciparum high-resolution
genetic linkage map (Su et al., 1999; Wellems et al., 1990). Leukocyte-free human red
blood cells (Indiana regional blood center,) were suspended in complete medium [RPMI
1640 with L-glutamine (Invitrogen) 50 mg/L hypoxanthine, and 25 mM HEPES; 0.5%
Albumax I (Invitrogen), 10 mg/L gentamicin, and 0.225% NaHCO3] at 4% hematocrit and
grown at 37°C in six-well culture plates, placed in a sealed environmental chamber (Billups-
Rothenberg), and gassed daily (mixture of 5% CO2, 5% O2, and 90% N2). Lines were
cultured for at least three cycles after thawing with a minimum doubling of parasitemia each
48 h cycle, prior to initiation of drug assays. No attempt was made to synchronize parasite
cultures; however, the process of thawing yielded partially synchronous parasite stages.
Dilutions to initiate assays were made from cultures between 1-5% parasitemia consisting of
greater than 75% ring stages. To minimize chances of genotype-phenotype shifts resulting
from mutation accumulation, parasite cultures were carried for a maximum of six weeks and
replicate testing was conducted on stocks closest to the original progeny (stock cultures are
frozen from short-term cultures).
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Drug stocks of chloroquine diphosphate (Sigma-Aldrich Co), verapamil hydrochloride
(Sigma-Aldrich Co), chlorpheniramine maleate (Sigma-Aldrich Co), and amitriptyline
hydrochloride (Sigma-Aldrich Co), were made in deionized water. A stock solution of
citalopram hydrobromide (Fisher Scientific) was made in 100% ethanol. Stock solutions of
probenecid (Avocado Research Chemicals) and desipramine (Sigma-Aldrich Co) were made
in DMSO. All solutions were stored at -20°C until use. Dilutions from these stocks were
made in low-hypoxanthine complete medium (low-HX CM; RPMI 1640 with L-glutamine,
2.94 μM HX, and 50 mM HEPES; 0.5% Albumax I, 10 μg/mL gentamicin, and 0.225%
NaHCO3). Drug assays based on [3H]-hypoxanthine incorporation were performed as
previously described (Ferdig et al., 2004); each biological replication was conducted
independently on different days for each parasite line. For inclusion in the assay, each
progeny clone was genotyped using a panel of 10 MS markers to ensure clonality and
confirm identity.
Percent inhibition was calculated by the formula:
IC50 values were determined by fitting data to a non-linear sigmoidal dose-response curve
(variable slope) using GraphPad Prism v4.0 software. Log transformed mean dose response
values were obtained from 5-22 independent measurements and were used for QTL analysis.
Isobologram analysis
To determine the presence and degree of reversibility in the parents of the genetic cross,
two-fold serial dilutions of the drug combinations of CQ and reversal agents were prepared
using fixed ratios. The starting concentrations of reversal agents for the serial dilutions were
adjusted to approximately center the IC50 doses in the range tested. The following CQ :
reversal agent volumetric ratios were used: 10:0, 9:1, 8:2, 7:3, 5:5, 3:7, 2:8, 1:9, and 0:10.
The first and last ratios include only one drug, either CQ or the reversal agent. FIC were
determined for each drug combination for both HB3 and Dd2 using the formula:
Additivity was defined as a FIC = 1 and synergism (reversibility) was defined as a FIC of ≤
0.5 (points lying below the diagonal line of additivity). The fixed dose ratio with the lowest
concentration of reversal agent that showed a synergistic interaction with CQ was used for
tests in the progeny.
QTL analyses
Genome-wide scans were performed using R/QTL (Broman et al., 2003) to detect single and
interacting QTL associated with drug responses in the HB3 × Dd2 genetic cross. Drug
responses were log transformed to approximate a normal distribution. Genome-wide
significance thresholds were determined by permutation testing (n=1000 permutations)
(Doerge and Churchill, 1996) and the strength of linkage of a locus to the trait was
expressed as a logarithm of odds (LOD) score. Loci that exceeded the 99th percentile (p <
0.01), 95th percentile (p < 0.05), and 37th percentile (p < 0.63) were used to identify highly
significant, significant, and suggestive QTL, respectively. The combined effects of all QTL
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detected for each trait were determined by multiple regression analysis for all significant and
suggestive QTL. Other statistical analyses were performed using GraphPad Prism v4.0.
Allele effects were determined by calculating the phenotypic mean at the peak marker for
each of the two possible genotypes.
Copy number determination
Pfmdr1 copy number was determined by TaqMan real-time PCR using an ABI 7700 as
reported previously (Rohrbach et al., 2006). The pfmdr1 probe was FAMTM (6-
carboxyfluorescein) labeled at the 5’ end, and the α-tubulin control probe was VICTM
labeled. Forty cycles were performed and fluorescence data were expressed as normalized
reporter signals, calculated by dividing the amount of reporter signal by the passive
reference signal. The assay was replicated four independent times and normalized to HB3.
Purification of Recombinant PfMDR1 and Reconstitution into PLs
High level expression of various isoforms of PfMDR1 with C-terminal-hexaHis detection
tags via the pPICZc expression vector (Invitrogen) in P. pastoris has been reported
previously (Amoah et al., 2007; Lekostaj et al., 2008a). Yeast were grown under standard
conditions, induced with 0.5% methanol medium for 21 h, mechanically lysed via a
modified glass bead method and membranes harboring PfMDR1 were isolated as described
(Amoah et al., 2007; Fritz et al., 1999). Proteoliposomes (PL) harboring purified PfMDR1
were prepared using methods described earlier for PfCRT (Lekostaj et al., 2008b). In brief,
total protein was determined using the amido black assay, crude yeast membranes (CM)
were solubilized with dodecyl maltoside (DM), and protein purified by nickel chelation
chromatography. CMs were diluted to 2 mg/ml in a Tris-based wash buffer [50 mM Tris-
HCl, 250 mM sucrose, 20% (v/v) glycerol, and 1 mM MgCl2 (pH 7.5), supplemented with 3
M NaCl] and centrifuged at 100,000g for 1 h. The washed pellet was resuspended at 2 mg/
mL in solubilization buffer (wash buffer supplemented with 500 mM NaCl and 1% DM).
The sample was rotated for 30 min, and centrifuged for 1 h at 100,000g. The detergent
extract was then applied to a His GraviTrap column (GE Healthcare) and allowed to flow
through via gravity. The column was washed with several bed volumes of 20 mM imidazole
to remove nonspecifically bound proteins, and PfMDR1 was eluted with 500 mM imidazole,
into polar Escherichia coli lipid suspension at a final concentration of 1.2% lipid. Protein-
lipid mixtures were rotated gently for 30 min and then dialyzed against 50 mM Tris-HCl,
250 mM sucrose, and 1 mM EDTA (pH 7.5) for 20 h. Purified PfMDR1 PLs were
centrifuged for 1 h at 100,000g, pellets were resuspended in fresh dialysis buffer, and snap-
frozen in dry ice-ethanol. Purified protein levels were redetermined using the amido black
assay.
Drug Competition with AzBCQ Photolabeling
The synthesis of AzBCQ and optimization of photolabeling conditions within a 96 well plate
format has been described in detail previously (Lekostaj et al., 2008b). Experiments with
PfMDR1 PLs were carried out with minor modifications (Pleeter et al., 2010). Briefly, a
fixed amount (4.0 μg per well) of purified PL protein was diluted in a 50 mM Mes-Tris
buffer at pH 5.2. The PL-buffer solution was aliquoted into wells of a 96-well UV
transparent plate. Either buffer or competing drug solution was added to each respective
well, followed by the addition of 0.5 mM AzBCQ. The plate was shaken at 650 rpm for 30 s
and then incubated for 10 min at 37°C in a water bath. The plate was then exposed to UV
radiation (254 nm maximum) at 1 cm distance lamp for 10 min. The reaction was quenched
with the addition of an equal volume of Laemmli sample buffer. The samples were again
incubated for 10 min at 37°C, divided in half, and loaded onto 2 parallel 7.5% bis-
acrylamide Tris-HCl gels. For AzBCQ photolabeling detection, blots were blocked in 10%
milk and probed with streptavidin-HRP (1:400). For quantitation of PfMDR1 protein
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present, C-terminal hexaHis tags were probed with the Qiagen PentaHis detection kit
according to the manufacturer’s instructions (Lekostaj et al., 2008b).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Isobolograms characterize drug interactions in Dd2 and HB3
Data points represent the FICs of various dose-combinations of (A) CQ+VP, (B) CQ+CT,
(C) CQ+PB, (D) CQ+AM, (E) CQ+DES and (F) CQ+CLM. Each isobologram represents
the interaction in both CQ resistant parent Dd2 (blue) and CQS parent HB3 (black). Points
near the solid line indicate an additive relationship between the two drugs; while those
above the line indicate antagonism those below the line indicate a synergistic relationship.
Synergistic interactions were observed for most drug combinations except CQ+PB. The CQ
+DES interaction plot showed weak synergism in HB3 and CQ+PB was additive for both
HB3 and Dd2.
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Fig. 2. Ranked plots showing phenotype distributions for CQ with and without VP
A. Ranked distribution for VP response against CQ response in the cross. VP response is
continuously distributed and inversely related to CQ response. Progeny that had high VP
IC50 values had lower CQ IC50 values. This negative relationship was consistent with all
other reversal agents tested.
B. Ranked distribution for CQ response against fold change in the presence of VP. Fold
change partitions the drug responses into two groups (CQS and CQ resistant) depending on
the HB3 and Dd2 pfcrt allele.
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Fig. 3. Relationship between CQ IC50 and CQ with VP response in CQS and CQ resistant
progeny
A. Relationship between CQ response with and without VP in CQS parasites. CQS progeny
exhibit a strong positive relationship between CQ response with and without VP (r = 0.80, p
< 0.0001), although this relationship reflects unchanged responses.
B. Relationship between CQ response with and without VP in CQ resistant parasites. CQ
resistant progeny exhibit a strong positive relationship between CQ response with and
without VP (r = 0.84, p < 0.0001), resulting from a significant reduction in CQ response in
the presence of VP.
C. Relationship between CQ response and fold change of CQ response in the presence of
VP. Correlation analysis detects no significant relationship between CQ response in CQ
resistant parasites and the fold change resulting from CQ+VP combination (r = 0.2, p >
0.05).
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Fig. 4. Genome-wide QTL scans
Three significance thresholds were determined by permutation testing. Highly significant (p
< 0.01), significant (p < 0.05), and suggestive (p < 0.63) LOD scores are represented by
horizontal lines on each scan. The abscissae show chromosomal location (14 chromosomes),
where the width of the chromosome number is proportional to the number of markers. All
traits (A) VP, (B) CLM, (C) CT, (D) CQ, and (E) CQ+VP map to chr 7 (20.2 cM) in the
region of pfcrt. A suggestive QTL on chr 5 (68.8 cM) in the region of pfmdr1 was detected
for (A) VP, (B) CLM, and (C) CT.
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Fig. 5. Allele effects at peak markers for QTL detected on chr 5 and 7
Effects of the Dd2 and HB3 alleles for response to VP, CLM, CT, and CQ at peak markers
for QTL: (A) chr 5 (68.8 cM) and (B) chr 7 (20.2 cM). Higher trait values were observed for
the HB3 alleles at both QTL for the reversal agents tested independently, whereas the higher
trait value for CQ response and fold change (degree of reversibility) were observed with the
Dd2 allele. (*p < 0.05, **p < 0.001, and ***p < 0.0001). Overlaid QTL for VP (blue), CLM
(red), and CT (black) for (C) chr 5 and (D) chr 7, respectively.
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Fig. 6. CQ drug responses in the progeny identifying additional QTL effects contributing to
extreme CQ drug response
A. Rank order plot of CQ response in the progeny of the cross. A greater than 10 fold
increase in IC50 divides the progeny into CQS and CQ resistant subsets. As a trait, this large
difference maps to pfcrt on chr 7 and explains greater than 95% of the total variation in the
cross. A steady increase in CQ resistant progeny is observed ranging from (266.5 - 771.0
nm).
B. Genome-wide QTL scan for CQ response in CQ resistant progeny. This QTL analysis
identifies two suggestive QTL (p < 0.63): one on chr 5 (68.8 cM) in the region of pfmdr1
and one on chr 7 (5.8 cM).
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C. Allele effects of peak markers of CQR QTL. Inheritance of the Dd2 allele at the QTL on
chr 5 (68.8 cM) confers low-level CQR, whereas the HB3 allele corresponds to higher CQR
levels. An opposite pattern is seen for the chr 7 QTL peak marker (5.8 cM). A combination
of H5D7 alleles combined with Dd2-type pfcrt results in the highest CQR levels, (*p < 0.05,
**p < 0.001, *** p < 0.0001).
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Fig. 7. Competition of AzBCQ labeling of 3D7, Dd2 and 7G8 isoforms of PfMDR1 by CQ and VP
In each photolabeling experiment, AzBCQ was present in a probe:protein molar ratio of
about 100:1. PfMDR1 was labeled at various drug:AzBCQ molar excess ratios indicated
below. All blots are representative of experiments conducted at least three times on at least
two preparations of purified PLs wherein similar data was observed. Lanes 1-3 are 3D7
PfMDR1, lanes 4-6 are Dd2 PfMDR1, and lanes 7-9 are 7G8 PfMDR1. Top panels:
Streptavidin-HRP detection of AzBCQ photolabeling with CQ competition. First lanes of
each isoform have no competitor; second lanes of each isoform have 48-fold excess CQ;
third lanes of each isoform have 80-fold excess CQ. Middle panels: Anti-PentaHis-HRP
detection of -6His tag present in all isoforms. Bottom panels: Streptavidin-HRP detection of
AzBCQ photolabeling with VP competition. First lanes have no competitor; second lanes
have 20-fold excess VP; third lanes have 40-fold excess VP.
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Table 1
Drug responses in the parents of the genetic cross.
Drugs n Mean ± SEM n Mean ± SEM
Dd2 IC50 (nM) HB3 IC50 (nM)
VP 21 2303 ± 245 5 14307 ± 3442
CLM 22 1976 ± 238 5 90446 ± 1902
CT 21 2082 ± 200 5 42276 ± 1771
CQ 18 422 ± 25.0 5 27.2 ± 0.94
CQ+VP 22 82.8 ± 4.42 5 25.9 ± 0.57
CQ+CLM 22 71.7 ± 3.71 5 20.6 ± 5.19
CQ+CT 21 117 ± 6.84 5 25.5 ± 0.78
CQ+AM 22 59.2 ± 3.12 5 25.4 ± 0.91
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